Collaboration and License Agreements - Additional Information (Details)								1 Months Ended							3 Months Ended				6 Months Ended	12 Months Ended
	Mar. 25, 2021 USD ($) $ / shares	Feb. 14, 2021 USD ($)	Feb. 14, 2021 USD ($) Program	Apr. 29, 2020 USD ($) Unit $ / shares shares	Feb. 28, 2020	May 31, 2018 USD ($)	Oct. 31, 2017 USD ($) shares	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) shares	Aug. 31, 2019 USD ($)	Sep. 30, 2018 USD ($) Antibodies	Jul. 31, 2018 USD ($) Product	May 31, 2018 USD ($) Program	Oct. 31, 2017 USD ($) shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 shares	Jun. 30, 2020 USD ($) shares	Mar. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	May 28, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost of revenue																				$ 65,865,000	$ 0	$ 0
Receivable from collaboration																				773,079,000	0
Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues																				169,874,000	44,498,000	711,000
License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues																				0	22,747,000	0
Collaboration Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues																				917,194,000	0	0
2020 GSK | Collaboration Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues																				917,200
GSK | Accrued Liabilities And Other Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable from collaboration																				773,100,000
2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue																				$ 91,500,000
2020 Stock Purchase Agreement | GGL
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares				6,626,027
Share purchase price per share | $ / shares				$ 37.73
Issuance of common stock				$ 250,000,000.0
Preliminary Collaboration Agreement | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans				4 years
Maximum percentage of right to perform details in connection with antibody product				20.00%
Termination description																				Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.
Number of units of account | Unit				4
Research and development expense																				$ 77,300,000	25,400,000
Collaboration type and program								The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the “Antibody Program”); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the “Vaccine Program”), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the “Functional Genomics Program”).
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs				72.50%
Antibody license transaction price				$ 43,300,000
Total revenues																	$ 43,300,000
Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs				27.50%
Preliminary Collaboration Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of separate programs | Program			3
Upfront payment receivable		$ 225,000,000.0	$ 225,000,000.0
Percentage of upfront payment receivable at effective date of agreement		50.00%	50.00%
Option exercise fee to be received		$ 300,000,000.0	$ 300,000,000.0
Preliminary Collaboration Agreement | 2021 GSK | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pre-defined regulatory milestone payment		200,000,000.0	$ 200,000,000.0
2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued				$ 206,700,000
Common stock price per share | $ / shares				$ 36.70
Premium received on sale price of common stock				$ 43,300,000
Definitive Collaboration Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of upfront payment receivable at execution date of agreement																							50.00%
2021 Stock Purchase Agreement | GGL
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares																1,924,927
Issuance of common stock		$ 120,000,000.0
2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued	$ 85,200,000
Common stock price per share | $ / shares	$ 52.70
Premium received on sale price of common stock	$ 34,800,000
2021 GSK Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans		3 years
Percentage of share development costs			50.00%
Percentage of share Profit and loss			50.00%
2021 GSK Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Premium received on sale price of common stock			$ 34,800,000
Research and development expense																				500,000
Upfront fee		$ 225,000,000.0
Collaboration Agreement Transaction Price Consideration		$ 259,800,000
2021 GSK Agreement | Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues															$ 168,300,000
Brii Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description						Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days’ written notice (if the terminating party has not exercised an option for such program) or 180 days’ notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party’s uncured material breach on 60 days’ written notice (or 30 days’ notice following failure to make payment).
Written notice period to terminate licensed program for uncured material breach													60 days
Written notice to terminate licensed program if exercise													180 days
Written notice to terminate licensed program if not exercise													30 days
Written notice period to terminate licensed program for failure to make payment													30 days
Brii Agreement | Development Programs Exercised by Vir
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee, low end of the range						low tens of millions
Regulatory milestone payment on licensed product, low end of the range													low tens of millions
Regulatory milestone payment on licensed product, high end of the range						$ 100,000,000.0							$ 100,000,000.0
Option exercise fee, high end of the range						50,000,000.0							50,000,000.0
Maximum Aggregate Sales Milestone Payments													$ 175,000,000.0
Brii Agreement | Development Programs Exercised by Brii
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of royalty payment to be received								high-teens to high-twenties
Regulatory milestone payment to be received								$ 30,000,000.0
Maximum sales milestone to pay								175,000,000.0									175,000,000.0		$ 175,000,000.0
Option exercise fee, low end of the range													mid-single-digit millions
Regulatory milestone payment on licensed product, low end of the range													mid-single-digit millions
Regulatory milestone payment on licensed product, high end of the range						30,000,000.0							$ 30,000,000.0
Range of royalty payment to be paid													mid-teens to the high-twenties
Option exercise fee, high end of the range						$ 20,000,000.0							$ 20,000,000.0
Maximum Aggregate Sales Milestone Payments													$ 175,000,000.0
Brii Agreement | Brii Bio Parent
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								2,700,000									2,700,000		2,700,000
Payment to collaborator resulting from program option exercise																			$ 10,000,000.0
Maximum number of development program granted from Vir to Brii | Program | Program													4
Maximum number of development program granted from Brii to Vir | Program | Program													4
Percentage of ordinary share equal to outstanding share													9.90%
Carrying value of investment at cost															$ 5,700,000
Option exercise fee received								20,000,000.0
Determined transaction price								$ 22,700,000
Brii Agreement | Brii Bio Parent | License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from Related Parties																				0	22,700,000
Brii Agreement | Brii Bio Parent | Biological Materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues																				$ 400,000	0
Brii Agreement | Brii Bio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payment obligation expiration period after first commercial sales						10 years
Contract liability						$ 3,800,000							$ 3,800,000
Brii Agreement | Alnylam Pharmaceuticals Inc | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment to collaborator resulting from program option exercise																	$ 10,000,000.0
Alnylam Agreement | Alnylam Pharmaceuticals Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares									1,111,111								1,111,111
Written notice period to terminate licensed program for uncured material breach														60 days
Written Notice period to terminate licensed program if under challenge														30 days
Royalty payment obligation expiration period after first commercial sales																				10 years
Value of shares transferred to collaborator							$ 800,000							$ 800,000
Upfront fee paid														$ 10,000,000.0
Maximum shares to be issued | shares							1,111,111							1,111,111
Estimated fair value of the derivative liability									$ 29,200,000									$ 29,200,000
Milestone payments paid																	$ 15,000,000.0	$ 15,000,000.0
Expenses incurred under agreement																				$ 11,200,000	11,500,000	18,100,000
Written notice period for termination of licensed program														90 days
Written notice period to terminate licensed program for failure to make payment														30 days
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of tiered royalties to pay on net sales of products							The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets.							low double-digits to mid-teens
Maximum milestone payment for achievement of specified development and regulatory														$ 190,000,000.0
Maximum aggregate sales milestone payment														$ 250,000,000.0
Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of tiered royalties to pay on net sales of products														high single-digits to the sub-teen double-digits
Maximum milestone payment for achievement of specified development and regulatory														$ 115,000,000.0
Maximum sales milestone payment														$ 100,000,000.0
Development and Manufacturing Collaboration Agreement | WuXi Biologics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description					the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days’ prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within 60 days.
Royalties payment range on net sales of licensed product					high single-digits to mid-teens
Rockefeller Agreement | Rockefeller
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description												The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days’ written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days’ written notice for the Company’s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company’s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement.
Written notice period to terminate agreement by company												60 days
Annual License Maintenance Fees												$ 1,000,000.0
Written notice period to terminate agreement by counterparty												90 days
Upfront fee paid												$ 300,000
Royalty obligation period from date of first commercial sale												12 years
Research and development expense under license agreement																				4,700,000	1,300,000	1,000,000.0
Rockefeller Agreement | Rockefeller | Infectious Disease Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payment for achievement of specified milestones												$ 80,300,000
Rockefeller Agreement | Rockefeller | Infectious Disease Product [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum number of products covered against milestone payment | Product												6
MedImmune Agreement | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product											mid-single-digits to sub-teen double-digits
MedImmune Agreement | MedImmune
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies to develop | Antibodies											2
License agreement upfront payment											$ 10,000,000.0
MedImmune Agreement | MedImmune | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description											The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days’ notice. Either party may terminate the MedImmune Agreement for cause for the other party’s uncured material breach on 60 days’ notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days’ written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.
Written notice period to terminate licensed program for uncured material breach											60 days
Maximum aggregate milestone payment for achievement of specified milestones											$ 331,500,000
Written notice period for termination of licensed program											120 days
Written Notice period to terminate licensed program if under challenges											30 days
2019 Xencor Agreement | Xencor | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Specified research and development expenses milestone payments																				$ 500,000	$ 300,000	$ 800,000
2019 Xencor Agreement | Xencor | HBV Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payments										$ 77,800,000
2019 Xencor Agreement | Xencor | Influenza A Research Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payments										$ 77,800,000
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product										low- to mid-single-digits
Maximum aggregate milestone payments										$ 155,500,000
Maximum aggregate development and regulatory milestone payments										17,800,000
Maximum aggregate commercial sales milestone payments										$ 60,000,000.0
2020 Xencor Agreement | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment expiration period																				12 years
Royalties based on net sales of licensed products																				mid-single-digits
Cost of revenue																				$ 52,700,000
2019 and 2020 Xencor Agreement member | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description																				The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days’ written notice. Either party may terminate each agreement for the other party’s uncured material breach upon 60 days’ written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days’ written notice if any of the Company’s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.
Written notice period for uncured material breach																				60 days
Written notice period for termination of licensed program																				60 days
Written Notice period to terminate licensed program if under challenges																				30 days
Written notice period to terminate licensed program for failure to make payment																				30 days